EcoR1 Capital — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
Kronos Bio was a clinical-stage biopharmaceutical company developing small molecule therapeutics that target deregulated transcription factor networks implicated in cancer.
BiotechNew York, US
Norbert Bischofberger, Ph.D.(Executive Officer, Director)Christopher Wilfong(Executive Officer)
BoardRebecka Belldegrun, M.D.(Director)Otello Stampacchia, Ph.D.(Director)David M. Tanen(Executive Officer, Director, Promoter)Arie S. Belldegrun, M.D.(Director)
Co-investorsGV (Google Ventures)Nextech InvestVida VenturesBlackRockCommodore CapitalInvus+2 more
Clinical-stage biotech developing neoantigen-targeted T cell receptor (TCR) therapies for cancer; acquired by AstraZeneca.
BiotechNew York, US
Carsten Linnemann, PhD(Executive Officer, Director, Promoter)Antonius N.M. Schumacher(Director)Fei Chen(Director)
BoardDavid M. Tanen(Director, Promoter)Helen Kim(Director)
Co-investorsJeito CapitalVida VenturesTPG
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.




